Shanghai RAAS Blood Products Co., Ltd. Stock: price and insider trades · China
上海莱士
No insider purchase over the last 90 days. The latest, by 胡维兵, was filed 21 Apr 2026.
Shanghai RAAS Blood Products Co., Ltd.: what insiders have been doing
Shanghai RAAS Blood Products Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). From 4 November 2025 to 4 November 2026, the disclosure feed for Shanghai RAAS Blood Products Co., Ltd. logged 1 filing by 1 insider.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €1,415, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 board member. One trade stands out by size: a purchase of €1,415 from 胡维兵, disclosed on 21 April 2026.
With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 521 companies we follow on the same exchange. The full history, which starts in 2022, counts 6 purchases against no sales.
The latest purchase dates back some time: it was published 201 days ago, on 21 April 2026.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -13.0%Entry CN¥5.63 · Close 03 Nov 2026 CN¥4.90
- -27.0%Entry CN¥6.71 · Close 03 Nov 2026 CN¥4.90
- -6.6%Entry CN¥6.81 · Close at T+90 CN¥6.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,000 shares100.0% of flowA股XSHESZSE:273000000482341730Canonical exit: 20 Jul 2026 (T+90)
- 7,500 shares100.0% of flowA股XSHESZSE:173000009695159420Canonical exit: 27 Jan 2026 (T+90)
- 727,900 shares49.6% of flowA股XSHESZSE:173000009552433180Canonical exit: 16 Dec 2025 (T+90)
- 38,000 shares100.0% of flowA股XSHESZSE:173000007381152800Canonical exit: 6 Jun 2024 (T+90)
- 280,000 shares21.7% of flowA股XSHESZSE:173000007353171500Canonical exit: 28 May 2024 (T+90)
- 410,000 shares28.7% of flowA股XSHESZSE:173000005700830750Canonical exit: 18 Oct 2022 (T+90)
6 of 6 declarations
About Shanghai RAAS Blood Products Co., Ltd.
Shanghai Laishi is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
